IRIS
FLAMMINI, Lisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.627
AS - Asia 3.354
EU - Europa 2.757
SA - Sud America 394
AF - Africa 210
Continente sconosciuto - Info sul continente non disponibili 124
OC - Oceania 2
Totale 12.468
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.489
SG - Singapore 1.101
CN - Cina 945
IT - Italia 669
VN - Vietnam 536
FI - Finlandia 422
SE - Svezia 385
IE - Irlanda 382
BR - Brasile 284
DE - Germania 249
HK - Hong Kong 229
BD - Bangladesh 152
ZA - Sudafrica 130
FR - Francia 126
UA - Ucraina 117
NL - Olanda 116
TR - Turchia 97
GB - Regno Unito 83
IN - India 80
CA - Canada 79
RU - Federazione Russa 51
AR - Argentina 39
CI - Costa d'Avorio 39
BE - Belgio 33
ES - Italia 27
MX - Messico 27
ID - Indonesia 24
JP - Giappone 24
PL - Polonia 24
KR - Corea 22
CO - Colombia 18
EC - Ecuador 18
PK - Pakistan 18
CZ - Repubblica Ceca 17
IQ - Iraq 16
PH - Filippine 14
AT - Austria 13
TH - Thailandia 11
TW - Taiwan 10
MY - Malesia 9
PY - Paraguay 9
RO - Romania 9
VE - Venezuela 9
SA - Arabia Saudita 8
UZ - Uzbekistan 8
CH - Svizzera 7
EG - Egitto 7
JO - Giordania 7
KE - Kenya 7
NP - Nepal 7
BO - Bolivia 6
CR - Costa Rica 6
PA - Panama 6
AZ - Azerbaigian 5
EU - Europa 5
HN - Honduras 5
MA - Marocco 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
ET - Etiopia 4
IR - Iran 4
JM - Giamaica 4
PS - Palestinian Territory 4
SC - Seychelles 4
AL - Albania 3
BB - Barbados 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LT - Lituania 3
NI - Nicaragua 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
TN - Tunisia 3
UY - Uruguay 3
AO - Angola 2
BH - Bahrain 2
BY - Bielorussia 2
CL - Cile 2
DZ - Algeria 2
GE - Georgia 2
HU - Ungheria 2
LB - Libano 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
BN - Brunei Darussalam 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
GA - Gabon 1
GT - Guatemala 1
GY - Guiana 1
HR - Croazia 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LY - Libia 1
Totale 12.342
Salva come PNG Salva come JPEG
Città #
Dallas 1.567
Singapore 621
Ashburn 509
San Jose 451
Chandler 398
Dublin 381
Santa Clara 315
Beijing 237
Ann Arbor 222
Parma 221
Hong Kong 211
Ho Chi Minh City 166
Dearborn 149
Jacksonville 147
Council Bluffs 132
Boardman 129
Johannesburg 127
New York 116
Hanoi 108
Los Angeles 87
Shanghai 87
Munich 84
Nanjing 78
Izmir 74
Milan 61
Princeton 60
Lauterbourg 58
Hefei 52
Chicago 42
Wilmington 40
Abidjan 39
Buffalo 38
Helsinki 38
Bremen 35
Toronto 34
Groningen 33
Brussels 30
San Mateo 29
Bangalore 27
Bologna 27
Kunming 26
São Paulo 26
Des Moines 25
Guangzhou 23
Moscow 23
Columbus 22
Haiphong 22
Hebei 22
Jinan 22
Da Nang 21
Montreal 20
Shenyang 20
Tokyo 20
Houston 19
Nanchang 19
London 18
Marseille 18
Rome 18
Seattle 18
Changsha 17
Frankfurt am Main 17
Fremont 16
The Dalles 16
Turku 16
Warsaw 16
Denver 15
Stockholm 15
Tianjin 15
Jakarta 13
Mexico City 13
Norwalk 13
Redmond 13
Reggio Emilia 13
Brno 12
Jiaxing 12
Manchester 12
Nuremberg 12
Phoenix 12
Brooklyn 11
Ottawa 11
Rio de Janeiro 11
Seoul 11
Atlanta 10
Chennai 10
Modena 10
Naples 10
Amsterdam 9
Boston 9
Can Tho 9
Guayaquil 9
Hangzhou 9
Montegaldella 9
Poplar 9
Grafing 8
Orem 8
Vienna 8
Woodbridge 8
Zhengzhou 8
Amman 7
Ankara 7
Totale 8.131
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.723
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 258
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 253
Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats 253
Development of inhalation powders containing lactic acid bacteria with antimicrobial activity against Pseudomonas aeruginosa 242
An Enhanced Dissolving Cyclosporin-A Inhalable Powder Efficiently Reduces SARS-CoV-2 Infection In Vitro 235
3D-printed chitosan-based scaffolds: An in vitro study of human skin cell growth and an in-vivo wound healing evaluation in experimental diabetes in rats 226
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 225
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 221
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 214
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 202
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 201
Human colonoid-derived monolayers and Caco-2: comparative analysis of inflammatory responses 198
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 194
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 184
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 184
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 182
Antitumoral effect of a nanotechnology-based photodynamic therapy. 182
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 180
Hake fish bone as a calcium source for efficient bone mineralization 179
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 177
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 175
Distinct Roles of α4β2 and α7 Nicotinic Receptors in the Modulation of Inflammatory Responses in TNBS-Induced Colitis 175
Novel Analgesic Agents Obtained by Molecular Hybridization of Orthosteric and Allosteric Ligands 172
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 171
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 171
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 168
Analgesic activity of new hybrid muscarinic agonists in mice 167
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 165
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 162
Rifaximin anti-inflammatory activity on bovine endometrium primary cell cultures: a preliminary study 160
Intestinal Hypoxia and reperfusion: role for Eph-ephrin system 159
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 157
Brain Pharmacokinetics of Non-Imidazole Biphenyl H3 Receptor Antagonists: a Liquid Chromatography/Electrospray-Mass Spectrometry and ex vivo Binding Study in Rats 156
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 156
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 154
Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity 147
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 147
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 146
Preliminary study of calcium balance and bone mineralization improvement by a new calcium supplement in growing rats 146
Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: preliminary pharmacological investigation. 143
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 139
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 139
Functional and morphological characterisation of human colonoid-derived monolayers under inflammatory conditions 137
Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats 134
Development and validation of a DESI-HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study. 134
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 132
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 130
Aminopyridine derivatives with anticholinesterase and antiamnesic activity 128
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 127
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 127
α7 Nicotinic Agonist AR-R17779 Protects Mice against 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis in a Spleen-Dependent Way 125
Analgesic effects mediated by muscarinic ligands acting at both orthosteric and allosteric receptor binding sites 117
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 115
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 114
Multi-target-directed ligands: new histamine H3 receptor antagonists with anticholinesterase activity 112
Liquid chromatography-mass spectrometric method for determination of the non-imidazole H(3) -receptor antagonist UPR1056 in rat plasma. 112
EphA2-ephrinA1 system in acute mesenteric inflammation due to ischemia-reperfusion in mice 112
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 111
In vitro pharmacology at human histamine H(3) receptors and brain access of non-imidazole alkylpiperidine derivatives. 111
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 108
Synthesis and characterization of new bivalent agents as melatonin- and histamine h3-ligands. 107
Novel potent N-Methyl-d-Aspartate (NMDA) receptor antagonists or s1 receptor ligands based on properly substituted 1,4-dioxane ring 105
Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors 105
Synthesis and stability in biological media of 1H-imidazole-1-carboxylates of ROS203, an antagonist of the histamine H3 receptor. 101
New selective PDE4D inhibitors devoid of sedative effects in mice 95
Pharmacological characterization of a new non-himidazole histamine H3 antagonist 92
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 88
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice 88
Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M1 and M2 77
CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases 32
Investigation on Drug Permeability in Control and Inflamed Human Colonoid-Derived Monolayers 4
Totale 12.468
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022354 0 0 25 48 24 17 32 32 18 27 13 118
2022/20231.393 168 170 84 106 129 154 30 63 407 14 53 15
2023/2024656 23 54 12 29 43 143 67 36 24 37 70 118
2024/20251.765 84 87 114 124 188 196 74 68 188 152 161 329
2025/20265.627 417 624 1.510 418 598 234 415 161 536 306 269 139
2026/2027552 135 272 145 0 0 0 0 0 0 0 0 0
Totale 12.468